For patients with locally advanced prostate cancer, neoadjuvant chemohormonal therapy (NCHT) is beneficial for biochemical progression-free survival (bPFS), according to a study published in The Journal of Urology. Co-lead authors Hongyang Qian, Chenfei Chi, and colleagues conducted a randomized trial including 141 patients with locally advanced, high-risk prostate cancer. They randomly assigned patients 2:1 to the NCHT group (docetaxel plus androgen deprivation therapy for six cycles) or the neoadjuvant hormone therapy (NHT) group (androgen deprivation therapy for 24 weeks). The primary endpoint was 3-year bPFS. The NCHT group had a significantly higher rate of 3-year bPFS versus the NHT group (29% vs 9.5%). The NCHT group also achieved a significantly longer median bPFS time than the NHT group with a median follow-up of 53 months (17 vs 14 months). There were no significant differences between groups in terms of pathological downstaging and minimal residual disease rates.
The post Neoadjuvant Chemohormonal Therapy Aids Locally Advanced Prostate Cancer first appeared on Physician's Weekly.